Assessing the Efficacy, Safety, and Tolerability of Met DR in Subjects With T2DM Over 12 Weeks

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 240 participants.

Also called NCT01819272

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 240 participants (enrolled count) (from the registry)
Sponsor
Elcelyx Therapeutics, Inc. (from the registry)
Registry
  • NCT NCT01819272
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Not reported
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01819272. Randomized; quadruple masking; primary purpose treatment. Start 2013-04 (registry gives no type); primary completion 2013-09 (actual). Results posted on 2015-09-21.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Assessing the Efficacy, Safety, and Tolerability of Met DR in Subjects With T2DM Over 12 Weeks
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Met DR
Intervention (Drug)
Met XR
Intervention (Drug)
Placebo
Lead sponsor
Elcelyx Therapeutics, Inc. (class: industry)

Record details

Record id
cardio:ct-nct01819272
Content hash
9e50830f062d01d94c8f6334336454f4c6e68613382a984e11e7fac0a33b28ab